Compare SHAK & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAK | ZLAB |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | China |
| Employees | N/A | 1797 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2014 | 2017 |
| Metric | SHAK | ZLAB |
|---|---|---|
| Price | $71.13 | $23.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 26 | 5 |
| Target Price | ★ $117.29 | $49.60 |
| AVG Volume (30 Days) | ★ 2.2M | 639.3K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 354.17 | 38.46 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $1,445,306,000.00 | $460,156,000.00 |
| Revenue This Year | $16.58 | $9.75 |
| Revenue Next Year | $15.07 | $26.03 |
| P/E Ratio | $190.05 | ★ N/A |
| Revenue Growth | ★ 15.38 | 15.33 |
| 52 Week Low | $51.60 | $15.96 |
| 52 Week High | $110.67 | $36.77 |
| Indicator | SHAK | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 66.47 | 64.39 |
| Support Level | $52.90 | $16.84 |
| Resistance Level | $97.35 | $25.28 |
| Average True Range (ATR) | 2.90 | 0.76 |
| MACD | 1.48 | -0.01 |
| Stochastic Oscillator | 79.32 | 76.29 |
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine, and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh-brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water. Geographically, the company generates the majority of its revenue from the United States.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.